^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + Campath (alemtuzumab) (CD52 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL with del(17p)/TP53 mutation...Other recommended regimens...Alemtuzumab ± rituximab
